Guardant Health, Inc. is a precision oncology company, which engages in the provision of treatment of cancer through the use of proprietary blood-based tests, vast data sets, and advanced analytics. The company is headquartered in Palo Alto, California and currently employs 1,999 full-time employees. The company went IPO on 2018-10-04. The company provides critical insights into what drives disease through its advanced blood and tissue tests, real-world data, and artificial intelligence (AI) analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and helping doctors select the treatment for patients with advanced cancer. For patients with advanced-stage cancer, it has developed Guardant360 laboratory developed test (LDT), and Guardant360 CDx test, a comprehensive liquid biopsy test to provide tumor mutation profiling with solid tumors and to be used as a companion diagnostic in connection with non-small cell lung cancer (NSCLC), and breast cancer. The company offers other tests, including Guardant360 Tissue test, Guardant Reveal blood test, Guardant360 Response blood test and others.
Follow-Up Questions
GH 주식의 가격 성능은 어떻습니까?
GH의 현재 가격은 $92.61이며, 전 거래일에 decreased 5.62% 하였습니다.
Guardant Health Inc의 주요 사업 주제나 업종은 무엇입니까?
Guardant Health Inc은 Health Care 업종에 속하며, 해당 부문은 Health Care입니다
Guardant Health Inc의 시가총액은 얼마입니까?
Guardant Health Inc의 현재 시가총액은 $11.5B입니다
Guardant Health Inc는 매수, 매도, 아니면 보유해야 하나요?
월스트리트 분석가들에 따르면, 27명의 분석가가 Guardant Health Inc에 대한 분석 평가를 실시했으며, 이는 13명의 강력한 매수, 16명의 매수, 3명의 보유, 1명의 매도, 그리고 13명의 강력한 매도를 포함합니다
